Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Herantis Pharma, Webcast, Q2'24

By Inderes8/22/2024, 7:00 AM
Herantis Pharma

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Antoine
00:01 - 13:05

Good morning. My name is Antoine. I'm the CEO of Ferrante's Pharma. And welcome to the first half remote report webinar for this pharma. So first, the necessary forward-looking statements. And let's go then into the company update followed by the first half report. Highlights. Here at Ferrante's Pharma, we are a clinical-stage public company and we develop disease-modifying therapies for Parkinson's disease and other neurodegenerative diseases. And our lead asset is HER-096. That is a peptide that mimics a CNF protein. And CNF protein has been earlier shown to break the cycle of Parkinson's disease pathogenesis. And last year we completed the Phase 1 clinical study with HER-096, demonstrating brain penetration and a good safety profile after subcutaneous administration. What is very specific for HER-096 is that we actually have signs of efficacy already in clinical settings, with the mother molecule, as we call it, the CNF, in the Phase 1 clinical study with fairly advanced Parkinson's patients. And this is truly unique. And combine this with the strong preclinical data of HER-096, demonstrating the mechanism of action, the activity in Parkinson's disease pathogenesis, and the ability to affect the symptoms in Parkinson's models is a great combination to work with and continue with the clinical development. I want to also highlight the team, both the operational team at the company. But our very experienced board and the advisory board, consisting of senior industry experts in the clinical development of therapeutics up to the market. So we believe that this is a great combination with the great biology that we are working with. So why is innovation needed for Parkinson's disease? The current therapies only treat symptoms. They don't affect disease progression. Currently, there is no cure for Parkinson's disease. And even with the current symptomatic treatment, it is not always efficacious. There are also significant side effects. So, it's clear that there is a high unmet clinical need and all the Parkinson's patients are really eagerly waiting for new types of drugs that can really slow down or even stop the progression of the disease, hopefully at the early stage of the disease, so that the patients can keep up with their normal life, which is currently not possible longer term. If you look at the market currently, the market size for Parkinson's disease therapeutics is approximately 5 billion USD, and it's expected to grow up to 10 billion by 2030. And this growth will be driven by the development of disease-modifying treatments, such as HER-096, and, based on our market research, we can have a big share of that market. That global market will be addressed once, and if HER-096 reaches the market. And these figures only show the potential in Parkinson's disease as we know. Also, the same kind of biology could be used also in other neurodegenerative diseases later on. About the mechanism of action. So Parkinson's disease is caused by the degeneration of neurons in a certain area in the midbrain. And a hallmark of that degeneration is one pathway called unfolded protein response pathway that is chronically activated in Parkinson's patients, resulting in neuron degeneration and eventually the death of the neurons. Uh, accumulation of toxic alpha-synuclein aggregates and neuroinflammation. And what we have been able to show in preclinical settings is that we can break this cycle and reprogram the neurons to act normally so that they can keep up with the normal functions and production of the dopamine that controls motor functions in humans. So the key advantages of HER-096 are its neuro-restorative properties. Uh, we have significant evidence of that. We can administer HER-096 subcutaneously, which is quite unique, as many of the disease-modifying drug candidates have to be delivered intracranially. And we have very good safety data in clinical settings already. So what is the status of the data currently? So could we have the video here? Yes. So what we have shown in preclinical settings is that we can affect the symptoms. In this video, the first mouse is a normal mouse walking over a bar in a walking test for motor coordination. The second mouse has induced Parkinson's-like pathology. And it's really struggling to coordinate its movements. Uh, and the third mouse, like the second one with pathology but treated subcutaneously with HER-096. And as you can see, we have been able to reduce the motor symptoms. We know that the improvement is due to the increased amount of dopamine in the brain, which is a result of stabilizing the unfolded protein response pathway, the target mechanism. And we have a truly robust data set demonstrating the whole chain from the mechanistic intervention in that pathway to the effect on the motor symptoms. And this is, of course, very encouraging. And this is what we aim to translate into patient studies going forward. Last year, we completed a Phase 1a clinical trial in healthy individuals. And there on the left-hand side, you see the results of the brain penetration. In that study, we demonstrated that after a single subcutaneous administration of HER-096, we were able to achieve a concentration of HER-096 in cerebrospinal fluid. So in the CNS, between 50 and 100 nanograms per mL. Uh, which is well within the therapeutic range of HER-096, as shown in preclinical settings. And on the right-hand side, there is a graph about the pharmacokinetics and the profile. The pharmacokinetic profile in plasma is very good and as expected. This data provides us a great starting point for a Phase 1b clinical trial that we expect to start later this year. The Phase 1b clinical trial is a necessary step from Phase 1a to the Phase 2 clinical trials. And in Phase 1b, the objectives are to first of all demonstrate the safety and tolerability of repeated dosing in Parkinson's patients, but also to study the pharmacokinetics and biological responses to HER-096 administration using biomarker data. In the study, we have up to 16 healthy individuals to complete the pharmacokinetic study. And then we have 20 to 24 Parkinson's patients who will be administered HER-096 subcutaneously twice a week for four weeks. And then we are, of course, closely monitoring the effects of HER-096 in these patients. And we are really enthusiastic about this study. It's great that we are now able to soon start the first study of HER-096 in actual patients. Um, so that's a great milestone for the company and an important preparation towards the Phase 2 clinical trials. And in Phase 2 studies. The objective is to demonstrate the safety. So, the effect of HER-096 on Parkinson's disease. And let's go now. Report and the results. So, first of all, about the business highlights from the first half. We submitted a clinical trial application for the Phase 1b Clinical Trial in May. And then that study will take place in Finland. And we expect soon to get the approval and start the clinical study by the end of the year. We also received a milestone payment of $750,000 from the EIC Accelerator grant that we originally obtained on April 23rd. Very happy about the events of the reporting period. On July 1st, we announced that we secured research funding from the European Innovation Council. Fox Foundation and Parkinson's UK through the Parkinson's Virtual Biotech. They will finance our Phase 1b Clinical Trial and advanced biomarker efforts. The board has also decided on a new options rights program for key personnel. Let's spend a minute discussing the research funding that we obtained from the Michael J. Fox Foundation and Parkinson's UK. These two charities are the leading charities for Parkinson's disease research globally, especially the Michael J. Fox Foundation. Fox's stamp on our program delivers quite a bit of value for us, preparing for the next clinical studies and also from a partnering point of view, as this strategy has made a scientific evaluation of our assets. And they believe that HER-096 is among the best candidates that could address the unmet clinical need of Parkinson's disease. And here I also want to highlight that, since April 2023, we have been able to secure 6.1 million of non-dilutive research funding from these charities and from the European Union through their European Innovation Council accelerator grant. And both of these finances have involved the scientific evaluation of our asset. And we are really happy about this. Combine this with the commitment of, uh, the European Innovation Council (EIC) fund, including direct equity investments of up to €15 million, from which we raised €1.5 million earlier. This is a great achievement for guarantees going forward. So maybe you will take us through the financials. Yes.

Tone Kvåle
13:05 - 15:10

I'm Tone Kvåle, the CFO of this company. For the first half of this year, you can see that the operating expenses are in line with the increased activities we have had in the first half. We have filed the CTA. We are also working to prepare for both the Phase 1b and Phase 2 clinical trials, which involve increased Clinical Manufacturing and Control (CMC) expenses. CMC relates to manufacturing and control processes. We are also developing a program for biomarkers. This explains where the expenses are allocated. To the left side of the slide, you can see the other operating income. That is the grant from the European Innovation Council. It was discussed earlier, and the loss for the year for the first half ended at -2.6 million euros. That increase relates to ramped-up activities. If you go to the next slide, you can see that the equity position has strengthened compared to the same period last year. We have a cash position of 3.4 million euros, which consists of cash in the bank. Additionally, we have moved money to our short-term fixed income fund to secure higher interest rates. That's a combination of strategies for managing our finances. We received 750,000 euros from the European Investment Bank in June. That's part of our cash reserves. However, just to note that the research funding of 3.6 million euros will be paid in three installments, and they are not in the bank as of today. We will receive these payments as we reach certain milestones. Cash flow from operating activities was -3 million euros, and we reported a positive equity of 2 million euros by the end of June. This is a strengthened position compared to the same period last year. That concludes what I want to share about the financials.

Antoine
15:11 - 16:18

Okay, thank you, Tone. That covers the first half report and the company update. As highlights, we believe that our HER-096 is among the best potential candidates for Parkinson's disease and other neurodegenerative diseases as a modifying therapy. There is great commercial potential for HER-096. We have the right ingredients, both in terms of the team and the asset. And now, during this and next year, we are preparing for the Phase 2 trials. That preparation includes running the Phase 1b clinical study, which is a significant milestone for the company. I think next we have a Q&A session. If you have any questions, please ask us, and we'll try to provide thorough answers.

Tone Kvåle
16:18 - 16:30

Yes, we have already received some questions, and we can start with those. Okay, can you explain the financial terms of the research funding agreement that we obtained from the European Innovation Council? Did you mean The Michael J. Fox Foundation and Parkinson's UK?

Unknown 1
16:31 - 16:31

Yeah.

Antoine
16:31 - 17:30

So basically, the research funding, €3.6 million, is a loan that the company needs to pay back if the project is successful. The agreement stipulates that if we attain a certain amount of gain from that project, we must pay 10% back to the charities until we have repaid four times the capital they provided. So, for the maximum $14.4 million. So when the company has earned 144 million, then we have had the obligation to pay back that 14.4 million. So we believe that this is a very good instrument for all parties involved.

Unknown 2
17:31 - 17:33

And, uh.

Antoine
17:33 - 17:59

We are really happy to have received that kind of external validation. So, we need to also value that very highly. We believe that having Michael J. Fox and Parkinson's UK taking part in our journey is very important going forward. For example, if we consider partnering on the program at some point in time during development.

Unknown 1
17:59 - 17:59

Yeah.

Tone Kvåle
18:00 - 18:09

And the next question is, what is the aim for the upcoming Phase 1b Clinical Trial? And do we expect to see any efficacy data from that?

Unknown 1
18:10 - 18:10

Yeah.

Antoine
18:10 - 19:15

So clearly the aim is to bridge from the phase 1b clinical trial in healthy individuals towards phase 2, and remembering that in phase 2, we believe that we need to treat the patients for a long time, maybe six months. Uh, so we need to have more safety data with the patient population, and that's clearly the aim. But of course, we also want to see biomarker-related endpoints in the study so that we can better understand the effects that HER-096 might have on the biology, allowing us to design Phase 2. The Phase 1b Clinical Trial is not designed to provide efficacy data. It requires a longer treatment and more patients. It's important to manage the expectations that there is a specific purpose for the Phase 1b Clinical Trial, and it's great if we achieve that. Yes.

Tone Kvåle
19:16 - 19:24

And next question is, since you know, you have secured €3.6 million in funding, are you fully funded until the start of the Phase 2 clinical trial?

Antoine
19:24 - 19:25

Maybe you will.

Unknown 1
19:25 - 19:26

Ask.

Tone Kvåle
19:26 - 20:25

Ask. Yes, with this funding and securing this Phase 1b Clinical Trial, we have cash into the second half of 2025. So we will be able to deliver the top-line data from the Phase 1b clinical trial, but with this money, we will not be ready to start our Phase 2 trial because there is a lot of preparation we need to do, especially on the CMC side. We need to consider allocating some time to raise additional funds, but we are pleased that we secured 3.6 million, enabling us to proceed with the Phase 1b clinical trial. Herantis and Parkinson UK. So that's a really big achievement, I think, for the company. In addition, we have more questions coming in. That's nice.

Antoine
20:27 - 21:10

Yes, the Phase 1b Clinical Trial is really important. In Phase 1b, we are testing our hypothesis about biomarkers and, of course, it's difficult to predict what the data will look like, but we believe that this gives us a good opportunity to design Phase 2 clinical studies. Overall, the biomarker program has advanced well and has been well-resourced due to the fact that we have received EIC funding, now also supplemented by the Michael J. Parkinson's UK financing. So we are quite pleased with the progress and the status of that program.

Tone Kvåle
21:11 - 21:16

Yes.

Antoine
21:19 - 21:47

As we discussed earlier, we believe that our HER-096 can be efficacious also in other indications, for example, Alzheimer's or ALS. And that's also something that we have data with, with, uh, CNV. Uh, program. So far, we haven't disclosed any data, and we are not yet ready to disclose any specific data about this. These studies that we are currently conducting.

Tone Kvåle
21:49 - 21:57

Which clinical study results are needed before potential partners would agree to a significant deal? Please provide the transcript or additional details so I can assist you effectively.

Unknown 1
21:57 - 21:59

That's an easy question.

Antoine
21:59 - 23:14

There is no clear cut answer. There are tens of companies interested in neurodegenerative diseases, including Parkinson's disease. Each of these companies has different objectives regarding the kind of asset they would like to acquire. So, um, it varies from the preclinical phase until the commercial phase. So there is no clear-cut answer. Of course, the Phase 1b Clinical Trial and the fact that it is the first time we administer HER-096 to Parkinson's disease patients. We believe that's a big milestone. Of course, we need to examine the data, and then determine if there is a match with the major player. Uh, we'll have the data when it's available. Having said that, it is also possible that a partnering deal could be done even earlier, as there have been cases before, and, as we have announced to the market earlier, we are having these discussions on a continuous basis with multiple pharma partners. So, we just need to wait and see.

Tone Kvåle
23:15 - 23:24

Which drugs currently in clinical trials for Parkinson's disease are you most worried about? Uh, as a competitor?

Antoine
23:26 - 24:18

A great question. Uh, and uh, my answer is that we are actually not worried about any of the competitors. We have a completely different mechanism of action compared to any other compounds in development. So, we are not directly competing with any of these. And actually, it would be great if there would be success in drug development for Parkinson's disease. This modification will pave the way for us in both regulatory and commercial aspects. Eventually, we believe that twenty years down the road, the best treatment will most likely be a combination of maybe two different drugs.

Unknown 1
24:18 - 24:20

Address.

Antoine
24:20 - 24:34

A little bit different is the Parkinson's disease pathology. Overall, I believe that the success in the field is also beneficial for us.

Tone Kvåle
24:35 - 24:41

The upcoming study is really twice a week. Optimal dosing? Not more frequently.

Antoine
24:43 - 25:20

A good, good question again. We have previously said that we believe the right administration regime would be from 1 to 3 doses per week based on the data from Phase 1 pharmacokinetics. We have selected two times a week. In Phase 1b, we believe that could be optimal. Of course, we are continuing the pharmacokinetic studies there. Based on those data, we have enough information to then plan what would be the administration in phase two clinical studies.

Tone Kvåle
25:21 - 25:33

Good. Uh, when do you expect to get the approval for the Phase 1b Clinical Trial application? How predictable is the application process? Or is it more like a black box?

Antoine
25:34 - 26:00

The application process for clinical trial applications in Europe changed last year. And currently, it's very much predictable. And, we expect to have the decision by Q3 so that we are able to start the clinical study during Q4 this year.

Tone Kvåle
26:01 - 26:15

How can early-onset Parkinson's disease patients participate voluntarily in the Phase 2 trial? What qualifications must these patients have to be a part of this voluntary trial?

Antoine
26:17 - 26:54

Uh, yes. The question is about the Phase 2 study. And of course, we haven't yet disclosed any details about a potential further Phase 2 study. And if we are running that, it could start earlier in 2026. So let's maybe not discuss that too much, but the Phase 1b Clinical Trial that is starting. We have the clinical site, which is a commercial site in Finland, CRC, and they recruit the patients. Conducting the CRC would be a route for the patients to participate in the study if they choose to do so.

Tone Kvåle
26:55 - 26:58

What are the main side effects of HER-096?

Antoine
26:58 - 27:48

A good question again, based on the data from Phase 1, the majority of the safety-related events have been linked to the actual administration. So, the subcutaneous administration is not specific to HER-096; it's more generally due to the administration route. But if we look at what biological effects HER-096 has, we haven't yet observed any systemic side effects due to HER-096. So currently, it seems that we have a pretty clean profile. However, having said that, the Phase 1b Clinical Trial is very important to understand more about the possible side effects in Parkinson's patients.

Tone Kvåle
27:50 - 27:53

I think that was the end of the questions we have received.

Unknown 1
27:54 - 27:54

All right.

Antoine
27:54 - 28:26

Thanks for the many very good questions. It was really a pleasure to have those questions. And thank you for listening. The webinar has concluded, and you are always welcome to contact us at Herantis or myself. We are happy to answer any questions, and hopefully, you will join future webinars with us and would like to continue following our great story. Thank you.

Unknown 1
28:27 - 28:27

Thank you.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…